Psoriatic Arthritis

An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.

The rheumatology month in review emphasizes new trends in medication use and novel technologies' potential for managing fibromyalgia.

A greater portion of patients treated with bimekizumab achieved minimal clinically important differences than with placebo.

Concomitantly, other treatment modalities such as physical and occupational therapy, anticonvulsants, topical analgesics, and psychosocial treatment have increased.

BIMZELX was previously approved for treating moderate-to-severe plaque psoriasis.

Gender, age, and disease duration significantly affected symptom variations.

Extended follow-up with more cases is ongoing and will allow risk factors for psoriatic arthritis to also be further explored.

There were also no significant differences in clinical parameters at baseline for patients initiating first-line or not first-line therapy.

All patients had persistent tumor responses, with 2 complete responses and 1 case of stable disease.

Types of occupation did not significantly affect response to treatment.

Notably, people with fewer vaccine doses were more likely to experience post-acute sequelae of COVID-19.

There were no differences in risk between patients with RA or PsA using or not using methotrexate.

Investigators analyzed levels of CXCL10, MMP3, S100A8, ACP5, and CCL2 in patients treated with biologics and methotrexate.

The rheumatology month in review emphasize's bimekizumab's efficacy in treating PsA and new risk factors and mitigators for developing gout or hyperuricemia.

Higher risk associations also included being a current smoker and socioeconomic deprivation.

More patients also switched from combination therapy to monotherapy at any time in both analyzed database populations.

Around 20% of participants had ultrasound evidence of at least 1 active enthesitis, and 15.7% had ultrasound signs of at least 1 active synovitis at examination.

A separate paper also found that the overall risk of serious infection was low in new users of targeted therapy.

A retrospective analysis compared data from the BE OPTIMAL and BE COMPLETE trials with data from pivotal trials of the IL-23–targeting therapies.

Adalimumab-aaty was FDA approved on May 23, 2023, and became commercially available in the US on July 2, 2023.

Similar trends were seen in study participants that transitioned from receiving placebo to bimekizumab after study week 16.

A new study revealed patients with chronic pain treated with opioid analgesics had a greater prevalence of opioid dependence, opioid use disorder, and aberrant behavior.

Subjects reported pain at the injection site was significantly reduced with the One-Press autoinjector pen and 98% chose the pen as their preferred medication delivery system.

The repository corticotropin injection is designed to help patients manage their medication alongside a range of chronic and acute autoimmune and inflammatory conditions.

Responders at week 104 demonstrated more significant changes from baseline and achieved normative values in PROs compared with non-responders.

Test your knowledge of juvenile idiopathic arthritis (JIA) treatment recommendations from the 2021 ACR guideline on JIA with this quiz.

PASI100 was achieved by 41.7% of patients at week 16 and 70.6% at week 260.

Most men (91.7%) and women (72.7%) with psoriatic arthritis exhibited sexual dysfunction.

Independent predictors of physical activity avoidance were anxiety symptoms—as determined by HADS—and the SF-36 Physical Component Score.

Test your knowledge of systemic juvenile idiopathic arthritis (JIA) treatment recommendations from the 2021 ACR guideline on JIA with this quiz.